Ultimately I have chosen to vote Yes, however in the meantime will keep it as a no to inspire another increase from Pfizer. If no additional announcements get made prior to kick off of any further increases to their offer; I will be changing my vote to Yes just before it counts.
I have no faith that our board can truly commercialise the technology and don't believe they will ever be able to steer RAP into a "going concern" as a business given cash burn rate and minimal revenue which if we are being honest with ourselves has been atrocious given the time-span they've had to make it happen. The BOD pay themselves more than what the company is able to generate and it isn't a sustainable business model to continue to do CR at investors' continual expenses.
Time to take off those rose-tinted glasses.
- Forums
- ASX - By Stock
- RAP
- Ann: Dispatch of Supplementary Scheme Booklet
Ann: Dispatch of Supplementary Scheme Booklet, page-10
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online